With an eye toward modernizing the care experience, San Jose, Calif.-based Outset Medical Inc. scored a major win, reporting this week that it raised $132 million in series D equity financing. The proceeds will go toward boosting production capabilities and speeding commercial expansion of the Tablo hemodialysis system in acute and chronic care markets in the U.S.

Amsterdam-based Wright Medical Group NV agreed to acquire Cartiva Inc., a private orthopedic company that focuses on treatment of osteoarthritis of the great toe. As part of the agreement, Wright will acquire 100 percent of Alpharetta, Ga.-based Cartiva's outstanding equity on a fully diluted basis for $435 million in cash.

There are a number of treatments for depression, including drug options and transcranial magnetic stimulation (TMS). Now, one company is looking to provide a treatment option to help those suffering from severe depression that delivers therapy in a fraction of the time.

Dublin-based Medtronic plc (NYSE:MDT) was up Tuesday after reporting revenue of $7.38 billion for the first quarter fiscal year 2019, which beat a consensus of $7.24 billion, Wells Fargo analysts noted. Medtronic hit $95.15 by the end of Tuesday, after closing at $90.03 the previous day.

Provista Diagnostics Inc., a relatively young New York-based company, is looking to help patients with abnormal or difficult-to-interpret mammograms with its Videssa Breast assay. To that end, the company recently completed a 28 state pilot commercialization program, with an eye toward a larger launch through strategic partners.

Many people who suffer from obsessive compulsive disorder (OCD) respond well to medication or psychotherapy. However, there are some who continue to experience symptoms. Now, the FDA has give the green light to the Brainsway deep transcranial magnetic stimulation (TMS) system, which could offer hope to these people.

Opioid-induced respiratory depression (OIRD) presents a major problem for hospitals. Now, Earlysense Ltd., of Ramat Gan, Israel, is highlighting study results showing that its contact-free system can detect and alert for the condition with high positive predictive value.

Irvine, Calif.-based Capillary Biomedical Inc. (CapBio), which is looking to combat failure points with current infusion sets, raised $2.9 million in a series seed funding led by the Cove Fund.